首页> 外文期刊>Nephron >Comment on 'Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade'
【24h】

Comment on 'Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade'

机译:评论“COVID-19涉及肾病学家?为什么和在多大程度上?新兴血管紧张素封锁的僵局”

获取原文
获取原文并翻译 | 示例
           

摘要

Dear Editor, We read with great interest the review article by Perico et al. [1] "Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade." The authors hypothesized that angiotensin receptor antagonists (ARBs) can prevent the entry of the novel coronavirus into the cell by changing the structure of angiotensin-converting enzyme 2 (ACE2). In addition, they said that ARBs may protect against acute respiratory distress syndrome (ARDS) by increasing the angiotensin 1-7 level. We think ARBs may exacerbate the 2019 novel coronavirus disease (COVID-19) infection by increasing the ACE2 level. We would like to point out that ARBs should be discontinued in COVID-19 infection.
机译:亲爱的编辑,我们非常感兴趣地阅读Perico等人的评论文章。 [1]“应该covid-19涉及肾病学家吗?为什么和在多大程度上?血管紧张素封锁的新兴普美爆炸性。” 作者假设血管紧张素受体拮抗剂(ARBS)通过改变血管紧张素转换酶2(ACE2)的结构,可以防止新的冠状病毒进入细胞中。 此外,他们表示,ARBS可以通过增加血管紧张素1-7水平来保护急性呼吸窘迫综合征(ARDS)。 我们认为ARBS可以通过增加ACE2水平加剧2019年新型冠状病毒疾病(Covid-19)感染。 我们要指出,ARBS应在Covid-19感染中停药。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号